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Abstract
OBJECTIVE: To study the effects of hydroxy safflow-
er yellow A (HSYA) on tumor capillary angiogenesis
in transplanted human gastric adenocarcinoma
BGC-823 tumors in nude mice.
METHODS: BGC-823 cells were injected subcutane-
ously into the right anterior armpit of nude mice to
establish an animal model of transplanted tumors.
After 24 h, 18 nude mice injected with tumor cells
were randomized into model, control, and HSYA
0.028 g/L groups, with six mice in each group.
Transplanted tumors were excised on day 20. Tu-
mor inhibition ratios were calculated for the trans-
planted tumors. Pathological changes and capillary
angiogenesis in the tumors were observed by light
microscopy.
RESULTS: Tumors in the model group grew more
quickly than those in the control and HSYA groups,
with inhibition ratios of 48% and 30%, respectively.
The microvessel count in the HSYA group was low-
er than in the model group (P<0.01), and microves-
sel density was also lower in the HSYA group (P<
0.05). Pathological changes were more obvious in
tumors in the model group compared to the HSYA
group.
CONCLUSION: HSYA inhibits the growth of trans-
planted BGC-823 tumors, and its effects on tumor
capillary angiogenesis may represent one of the
mechanisms responsible for this antineoplastic ef-
fect.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Hydroxy safflower yellow A (HSYA) is a monomer and
one of the main active ingredients of the traditional
Chinese drug Honghua (Carthamus tinctorius L.),
which is believed to activate blood circulation and dissi-
pate blood stasis. Recent research into safflower yellow
and HSYA has concentrated on its roles in myocardial
protection, lowering blood pressure, anticoagulation,
inhibition of thrombopoiesis, antioxidation, and neu-
ral and immune activities[1], and its anti-tumor activi-
ties have rarely been investigated[2-4]. An earlier study,
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however, indicated that HSYA could inhibit the abnor-
mal proliferation of ECV304 human umbilical vein en-
dothelial cells stimulated by LS180 colorectal cancer
cell lines[2]. HYSA also reduced the weight of BGC-823
transplanted tumors, slowed neoplastic cell prolifera-
tion and promoted oncocyte karyorrhexis to inhibit tu-
mor growth[3]. The current study investigated the ef-
fects of HSYA on pathological capillary angiogenesis in
subcutaneous transplanted BGC-823 human gastric ad-
enocarcinoma tumors in nude mice. The results will
provide experimental evidence to clarify the pharmaco-
logical actions of Honghua and support its clinical ap-
plications for the treatment of tumors.
MATERIALS ANDMETHODS
Animals and tumor cell line
Eighteen BALB/C (nu/nu) specific pathogen-free
(SPF) nude mice (9 male, 9 female), aged 4-6 w, weigh-
ing 16±2 g, were supplied by the Laboratory Animal
Center of the Cancer Institute, Chinese Academy of
Medical Sciences (Beijing, China, License No. SCXK
(Jing) 2004-0001). The human gastric adenocarcino-
ma cell line BGC-823 (poorly differentiated, Figure 1)
was provided by the Beijing Institute for Cancer Re-
search (Beijing, China).
Figure 1 BGC-823 cells.
Experimental drugs
HSYA was provided by the Beijing Institute for Heart
Lung and Blood Vessel Diseases (Beijing, China). The
stock solution was 397.2 g/L and the purity was
98.9% , as determined by high performance liquid
chromatography. The solution was stored at -20°C. Cy-
clophosphamide (CTX) for injection was supplied as a
white powder, 200 mg/ampoule, product lot No.
08012721 (Jiangsu Heng Rui Medicine Co. Ltd., Li-
anyungang, China).
Main reagents
Dulbecco's minimum essential medium (DMEM) and
fetal calf serum were from Gibco BRL Co. Ltd. (Gaith-
ersburg, MD, USA), mouse-anti-human CD34 mono-
clonal antibody (dilution 1:50) was provided by Ameri-
ca Neomarkers Co. (Fremont, CA, USA), normal cap-
rine blood serum, streptavidin-biotin complex (SABC)
immunohistochemistry kit, diaminobenzidine (DAB)
color reagent kit, and Hematoxylin afterstain kit were
all made by Zhongshan Golden Bridge Biotechnology
Co. Ltd. (Beijing, China). Reagents for cell culture and
immunohistochemistry, as well as 10% neutral forma-
lin solution, were prepared by the laboratory of the
School of Basic Medical Sciences, Beijing University of
Chinese Medicine, Beijing, China.
Instruments
The following equipment was supplied as indicated:
HERA Cell-CO2 Incubator (Heraeus Co., Hanau, Ger-
many), Guwei Superclean bench (Beijing Great Wall
Equipment & Engineering Co. For Air Purification,
Beijing, China), 3K30 high-speed refrigerated centri-
fuge (Sigma Hydroextractor Co. Ltd, Steinheim, Ger-
many), RM2135 Histotome (LEICA Co., Solms, Ger-
many), NIKON-TE2000 fluorescence inverted micro-
scope (Nikon Co., Tokyo, Japan), COOLPIX4500 dig-
ital camera (Nikon Co., Tokyo, Japan), Image-Pro Plus
6.0 image analysis system (America Media Cybernetics
Co., Bethesda, MD, USA).
Cell culture and nude mice breeding
BGC-823 cells were inoculated into culture bottles
with DMEM nutrient medium contained 10% inacti-
vated fetal calf serum, 100 U/mL benzylpenicillin and
100 mg/L streptomycin, and then cultured in an incu-
bator at 37°C and 5% saturated humidity CO2. A mix-
ture of 0.25% trypsin-0.2% ethylenediamine tetraace-
tic acid (EDTA)-D'Hanks solution was used for diges-
tion and passage of cells. Nude mice were bred in an
animal house (SPF) with a barrier system including a
sterile laminar flow chamber, in the Laboratory Animal
Center of the Cancer Institute of the Chinese Academy
of Medical Sciences. Mice were used for experiments af-
ter 1 week of acclimatization with free access to diet
and water. Animal feed was sterilized with Co60 (Certifi-
cate No. SCXK (Jing) 2005-0007, provided by Beijing
Ke'ao Xieli Animal Feeds Co. Ltd., Beijing, China).
Drug dispensing
Adequate amounts of thawed HSYA standard and
physiological saline were used to prepare the HSYA so-
lution at a concentration of 0.028 g/L. The solution
was filtered and sterilized using a 0.22-μm millipore fil-
ter, and then stored at -20°C after aseptic packaging, to
avoid thermal decomposition. The reference solution,
CTX, was prepared at a concentration of 2 mg/mL
with physiological saline.
Modeling
Once the BGC-823 tumor cells reached an adequate
number after passaging, and the adherent cells were in
exponential growth, tumor cells were digested and cen-
trifuged with alimentary juice consisting of 0.25%
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trypsin-0.2% EDTA-D'Hanks solution. Some cells
were stained with 0.4% trypan blue solution and
counted under an inverted microscope (× 100). If the
cell viability was >95% , a single cell suspension was
prepared at 2.15 × 107/mL, and 0.2 mL suspension
(about 4.3×106 cells) was inoculated subcutaneously in-
to the right armpit of each nude mouse to establish the
mouse BGC-823 tumor transplant model.
Animal grouping and drug administration
At 24 h after inoculation, mice were divided into three
groups of six mice each: a model group, a control
group, and an HSYA group, using computer random
number generation. From the day after inoculation,
the model and HSYA groups were administered 0.9%
sodium chloride 0.2 mL and 0.028 g/L HSYA 0.2 mL
by intraperitoneal injection, twice daily at 4-6-h inter-
vals. From the third day after inoculation, the control
group was administered CTX 0.2 mL by intraperitone-
al injection once every 2 days.
Tumor inhibition ratio
On the 20th day after inoculation, the mice were
weighed, and killed by cervical dislocation. The bodies
were routinely sterilized, and the tumors were com-
pletely excised. The tumors were weighed and the tu-
mor inhibition ratio (IR) was calculated as follows: IR=
(average tumor weight in model group - average tumor
weight in HSYA group)/average tumor weight in mod-
el group × 100%.
Histopathology
Fresh tumor tissues were fixed in neutral formalin solu-
tion, dehydrated routinely, embedded in paraffin, and
serial sections were cut at 4 μm. The sections were
dried at 50° C, stained with hematoxylin, and rinsed
with tap water. They were then processed with 70% sa-
line ethanol to separate the color, rinsed, restained with
acidizing eosin (HE), rinsed again, dehydrated, and
cleared. Finally the sections were mounted with neutral
balsam and examined under an inverted microscope.
Mesenchymal angiogenesis in the tumors was recorded
in 200 fields-of-view, to observe oncopathological
changes.
Analysis of microvessel density (MVD) by
immunohistochemistry
Immunohistochemical staining with CD34 monoclo-
nal antibody was used to mark vascular endothelium in
the tumor tissues[5]. Sections were doused in 2% 3-ami-
nopropyltriethoxysilane acetone solution for 30 sec-
onds, deparaffinized, and incubated with 3% H2O2 at
room temperature for 10 min. They were then put into
0.01 M citric acid buffer for antigen retrieval and mi-
crowaved for 20 min. Reagent A (normal caprine
blood serum fluid) was dropped onto the sections,
which were incubated at 37° C for 10 min. CD34
monoclonal antibody (1st antibody) was added fol-
lowed by incubation at 37° C for 2-3 h, refrigeration
overnight at 4° C, and rinsing with 0.1M phosphate
buffer saline (PBS). PBS buffer (0.01M) was used in
place of the 1st antibody as a negative control. The sec-
tions were treated with reagent B (the biotinylated anti-
body (sheep-anti-mouse IgG) (dilution 1:200)) and in-
cubated at 37°C for 30 min before the addition of re-
agent C (streptomycin-horseradish peroxidase) and fur-
ther incubation at 37° C 30 min. The sections were
stained with DAB, then stained with hematoxylin for a
further 1 min, dehydrated with graded alcohols, and
mounted with neutral balsam. The numbers of mi-
crovessels were counted and photos were taken under
an inverted microscope. The photos were analyzed us-
ing image analysis software.
Analysis of sections
1) Determination of microvessels: CD34 is a highly-ex-
pressed specific adhesion molecule on vascular endothe-
lial cells (VECs). VECs expressing CD34 in cancer
nests are identified by buffy/brown cytoplasmic stain-
ing, against a background of light blue nuclei. The in-
terstitial tissue, except for the blood vessels, is un-
stained. Every individual endothelial cell or endothelio-
cyte cluster that was stained buffy/brown, with its adja-
cent vessel, tumor cells and other linking tissue was
counted as one microvessel. The presence of a vessel lu-
men was not an essential criterion. 2) MVD: microves-
sels were counted according to the methods recom-
mended by Weidner[6]. The whole section was first
scanned at low magnification (×100) to identify three
regions with high blood vessel densities (hot spot re-
gions of neovascularization); these were then observed
at higher magnification (×400) to count the microves-
sels in each region. The mean count from three visual
fields was taken as the MVD value of the sample.
Large vessels with thick muscular walls and lumens
over eight hemocytes were not counted. Microvessels
in regions with tumor necrosis, cirrhosis, and few onco-
cytes were also excluded. 3) Image analysis: hot spot re-
gions of neovessels were selected randomly in each sec-
tion and photographed at a magnification of × 400.
One photograph was chosen randomly from the total
18 photographs and was analyzed using Image-Pro
Plus 6.0 image analysis. The integrated optical density
(IOD) of the buffy/brown positively-stained region
was measured for semiquantitative determination.
Statistical analysis
The data were expressed as mean±sd and analyzed us-
ing one-way analysis of variance (ANOVA), with the
Statistical Package for the Social Science (SPSS) 13.0
(IBM, Armonk, NY, USA). P<0.05 was regarded as a
statistically significant difference.
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RESULTS
Tumor inhibition ratio
The IRs in the HSYA and CTX groups were 30% and
48%, respectively. This suggests that 0.028 g/L HSYA
had an inhibitory effect on BGC-823 tumors in nude
mice.
Tumor capillary angiogenesis
Blood vessels in BGC-823 transplanted tumors were
stained red by HE under the inverted microscope, and
occurred mainly in the marginal parts of the tumor.
Angiogenesis in the tumor interstitial tissues was obvi-
ous in the model group, accompanied by more mi-
crovessels, obvious cancer cell infiltration surrounding
the vessels and in the lumens, and some destruction of
vessel walls. Cancer cells were less concentrated and an-
giogenesis was less obvious in the control and HSYA
groups (Figure 2).
Figure 2 Pathology of BGC-823 transplantation tumors in each group (200×, HE staining). A: Model group; B: CTX group; C: HSYA
group.
Figure 3 CD34 immunohistochemistry for BGC-823 transplantation tumors (400×). A: Model group; B: CTX group; C: HSYA group.
Effect of HSYA on MVD in BGC-823 transplanted
tumors
1) Observation of MVD under the microscope: immu-
nohistochemical staining revealed MVD, as shown as
Figure 3. The hot spot regions of neovessels were near
the border of the tumor tissues, and staining was seen
in the cytoplasm of the VECs. More single or clustered
neovascular endothelial cells stained buffy/brown were
seen in the model group, and these cells were distribut-
ed extensively and irregularly. There were few obvious
vessel lumens in the model group. Fewer endothelial
cells were stained in the CTX and HSYA groups. 2)
MVD count: MVD was significantly lower in the
HSYA group compared to the model group (P<0.05).
MVD in the CTX group was also lower than in the
model group (P<0.01) (Table 1 and Figure 4). 3)
MVD image analysis: The darker the staining, the
higher the IOD value. The IOD values for the VEC cy-
toplasm were significantly lower in the control and
HSYA groups compared to the model group (P<0.05)
(Table 2 and Figure 5).
Table 1 Effect of HSYA on Microvessel Density (MVD) in
BGC-823 transplanted tumors ( xˉ ±s)
Group
Model
CTX
HSYA
Dose (g/L)
--
2.0
0.028
N
6
6
6
Photo
graphs
18
18
18
MVD
26.72±5.72
13.78±2.71**
20.05±4.56*
Notes: * P<0.05; ** P<0.01 vs. the model group.
Table 2 Image Analysis of microvessels stained by immuno-
histochemistry in BGC-823 transplanted tumors ( xˉ ±s)
Group
Model
CTX
HSYA
Dose (g/L)
--
2.0
0.028
N
6
6
6
IOD
152.78±89.11
63.33±32.90*
82.86±23.94*
Figure 4 Mean microvessel counts of BGC-823 transplanta-
tion tumors. Notes: * P<0.05; ** P<0.01 vs. the model group.
Figure 5 Integrated optical density (IOD) of BGC-823 trans-
plantation tumors. Note: *P<0.05 vs. the model group.
A B C
A B C
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DISCUSSION
Theoretical basis for treatment of tumor
angiogenesis
Previous oncological studies have concentrated on the
tumor cells themselves, rather than on the interstitial
portion; however, all solid tumors include parenchyma
and interstitial tissue, and support and nutrition from
the interstitial tissue, and interactions between the in-
terstitial substances and tumor cells, are essential for tu-
mor growth. Blood vessels are an important compo-
nent of the tumor interstitial tissue[7]. Since the theory
of neovascularization was first reported in 1971[8], the
role of blood vessels in the tumor interstitial substance
has featured highly in cancer research. Angiogenesis is
necessary for almost every step of tumor growth, inva-
sion and metastasis, and the tumor vascular system has
been confirmed as a key criterion in tumor classifica-
tion. Research has shown that most solid tumors with
a diameter >2-3 mm need to induce angiogenesis in or-
der to continue to grow actively[9] (Figure 6). When
host blood vessels grow into the tumor, they are able to
supply nutrients to the tumor cells directly[10], allowing
them to proliferate rapidly, thus increasing the risk of
metastasis and making therapy more difficult. Tumor
angiogenesis may therefore be necessary for tumor exis-
tence. Many studies have confirmed that microvessels
are more abundant in tumor tissues than in normal tis-
sues, and that more tumor microvessels are associated
with an increased chance of tumor cells penetrating in-
to the blood circulation. For example, the MVD of
colorectal carcinoma tissue has been positively correlat-
ed with metastasis and recurrence[11,12]. It has been sug-
gested that a tumor microvessel count>65 (at×400) is
associated with an increased risk of postoperative me-
tastasis and recurrence[13]. Inhibition of tumor angio-
genesis would therefore improve the outcomes of can-
cer treatment.
The inhibition of tumor angiogenesis has recently be-
come a supplementary or alternative approach in anti-
cancer therapy. Many therapeutic schedules aimed at
inhibiting neovascularization or targeting tumor vessels
have proved successful in mouse tumor models[14]. Re-
search into the effects of drugs on tumor angiogenesis
will aid understanding of the mechanisms of cancer
growth, as well as providing potentially valuable clini-
cal information.
Inhibitory effects of HSYA on tumor angiogenesis
The nude mouse model of human gastric adenocarci-
noma currently represents the closest experimental ani-
mal model for human gastric cancer, with a short mod-
eling time and relatively high model establishment rate
[15]. This model was therefore used to examine tumor
microvasculature in the current study. CTX was used
as a positive control. Studies have shown that low doses
of oral CTX of 25 mg/kg/d not only directly inhibited
endothelial cells, but also reduced the expression of ba-
sic fibroblast growth factor to inhibit angiogenesis in
an in vivo experiment[16]. CTX also induced the expres-
sion of thrombospondin-1 to block angiogenesis[17].
Pathological examination of tumor tissue is the most ef-
fective method for assessing angiogenesis. The results
of the current study clearly demonstrated angiogenesis
in the interstitial tissue of BGC-823 transplanted tu-
mors, while microvessels were less obvious in the
HSYA group. This suggests that HSYA could inhibit
the neovascularization of tumor tissue.
MVD, as reported by Weidner, represents a quantita-
tive index for judging the degree of tumor vasculariza-
tion[18]. It is closely related to tumor development, infil-
tration, metastasis and prognosis. CD34 is a marker
for vascular endothelial cells, with high specificity and
reproducibility[19]. Most tumor parenchymal cells show
no CD34 expression, while expression in the tumor in-
terstitial tissue only occurs in the VECs. CD34 label-
ing with CD34 monoclonal antibody can thus selec-
tively and clearly identify VECs. Quantitative analysis
of angiogenesis currently involves use of automated
counting or computer image analysis systems, the latter
being quicker and more accurate, with good repeatabili-
ty. Computer image analysis can also detect a range of
morphological parameter indexes of tumor angiogene-
sis with potential prognostic value[20].
To reinforce the objectiveness of angiogenesis evalua-
tion, the current study simultaneously used two obser-
vation methods to analyze MVD: microvessel counting
and average optical density value. Both techniques re-
vealed fewer microvessels in the HSYA group com-
pared to the model group. Together with the results of
HE staining, this confirmed that HSYA, an ingredient
of Honghua known to activate the blood circulation,
also played a role in decreasing MVD in BGC-823
transplanted tumors. This confirmed the results of
Wang's study, which suggested that a decoction of
Honghua could inhibit H22 transplanted tumors by re-
ducing MVD and inhibiting angiogenesis[21]. Another
study showed that curcumin, the active ingredient of Ji-
anghuang (Rhizoma Curcumae longae), could inhibit
the proliferation and migration of bovine endothelial
cells stimulated by tumor-cell-conditioned medium[22].
In addition, tranethylpyrazine, an ingredient of Rhi-
zoma Chuanxiong, could antagonize the proliferation
of ECV304 cells and prevent endothelial cells from ex-
pressing KDR (kinase insert domain-containing recep-
tor)/Flk-1 (fetal liver kinase-1) to inhibit angiogenesis[23,
24]. We therefore concluded that the ability of HSYA to
decrease tumor MVD was probably related to its inhi-
bition of vascular endothelial cytoactivity and inhibi-
tion of the release of proangiogenic factors. The effec-
tiveness of all Chinese herbs, however, is the result of
interactions between many active components and the
human body.
This study confirmed that HSYA can antagonize tu-
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mor angiogenesis, at least partly via its inhibition of tu-
mor vascularization. Clarification of the pharmacologic
actions of HSYA will aid in the development of future
clinical anticancer applications of Honghua.
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